独家直击！宿命之战即将上演！电影《困兽》发布“赌城风云”预告 10月27日强势登陆全国院线

宿命之战即将上演！电影《困兽》发布“赌城风云”预告 10月27日强势登陆全国院线

北京 - 2024年6月14日 - 由彭发执导，钟汉良、吴镇宇、张兆辉领衔主演，胡杏儿特别出演的犯罪电影《困兽》今日发布“赌城风云”版预告，正式定档10月27日全国上映。影片以“虎城”为背景，讲述了由一起离奇的失踪案引发的黑白两道殊死较量的故事。

在“赌城风云”版预告中，信息量十足，节奏紧张刺激。钟汉良饰演的警察吴文辉，吴镇宇饰演的黑帮大佬华森，张兆辉饰演的商业调查员何舜英三人各怀心思，针锋相对，陷入了利益与正义、法律与欲望的漩涡之中。随着剧情的推进，一场场惊心动魄的较量和反转接踵而至，将观众带入一个充满悬疑和阴谋的灰色世界。

预告片中，钟汉良一身警服，眼神坚毅，正气凛然，展现了警察吴文辉不畏强权、誓死追查真相的决心。吴镇宇饰演的黑帮大佬华森气场强大，阴险狠辣，将狠辣无情的反派角色演绎得入木三分。张兆辉饰演的商业调查员何舜英则游走在黑白两道之间，心思难测，为影片增添了不少悬念。

电影《困兽》改编自同名小说，由曾执导过《无招》、《全城追缉》等作品的彭发导演执导。影片集结了钟汉良、吴镇宇、张兆辉等实力派演员，演技飙升，看点十足。此外，影片还汇集了香港电影的黄金班底，制作精良，品质保证。

《困兽》的定档，也为即将到来的国庆档电影市场注入了新的活力。影片将于10月27日全国上映，即将上演一场正邪交锋、宿命对决的精彩好戏，敬请期待！

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.